Journal profile · ONCOLOGY-HEMATOLOGY
Clinical Lymphoma Myeloma & Leukemia
ISSN 2152-2650 · eISSN 2152-2669 · Cancer Media Group · UNITED STATES · Bimonthly · Founded 2010
Clinical Lymphoma Myeloma & Leukemia: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.9; hybrid open access; APC about USD 3,890; median 44 days to acceptance (101 articles, last 24 months); community-reported acceptance: fairly easy; 3,476 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Clinical Lymphoma Myeloma & Leukemia is published by Cancer Media Group and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Multiple Myeloma Research and Treatments, Chronic Lymphocytic Leukemia Research and Lymphoma Diagnosis and Treatment, together about 37.9% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Clinical Lymphoma, Myeloma and Leukemia Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. More Society Affiliations More
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY-HEMATOLOGY
Editor-in-chief Sagar LonialPublisher website
Editorial board by country: none in mainland China; most named United States 59, France 3, Italy 3, Greece 3, United Kingdom 2 (84 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Multiple Myeloma Research and TreatmentsMedicine16%
- Chronic Lymphocytic Leukemia ResearchMedicine11.8%
- Lymphoma Diagnosis and TreatmentMedicine10.1%
- Acute Myeloid Leukemia ResearchMedicine9.6%
- Chronic Myeloid Leukemia TreatmentsMedicine9.3%
- Acute Lymphoblastic Leukemia researchMedicine5.6%
- Myeloproliferative Neoplasms: Diagnosis and TreatmentMedicine5.6%
- CAR-T cell therapy researchMedicine5.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 4 |
| Minor | Hematology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.9LetPub ·
- Impact factor (publisher)
- 4.1Publisher website ·
- CiteScore 2026-06
- 2.6LetPub ·
- CiteScore (publisher)
- 2.6Publisher website ·
- SJR 2026-06
- 0.62LetPub ·
- SNIP 2026-06
- 0.74LetPub ·
- h-index
- 67OpenAlex ·
- i10-index
- 1,392OpenAlex ·
- 2-year mean citedness
- 0.25OpenAlex ·
- Self-citation rate
- 4.9%LetPub ·
- Share of gold OA articles
- 23.66%LetPub ·
Volume
- Articles per year
- 208LetPub ·
Articles by year OpenAlex count · 20,315 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 3,832 | 65 | 56 |
| 2025 | 3,476 | 163 | 795 |
| 2024 | 2,200 | 125 | 1,485 |
| 2023 | 2,000 | 772 | 1,687 |
| 2022 | 1,575 | 125 | 1,901 |
| 2021 | 1,396 | 139 | 3,399 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
44 daysMedian, submission to acceptance · P25–P75 29 days – 58 days
- Acceptance to online
- median 4 days (101 articles)
- Submission to online
- median 49 days
- Sample
- 101 articles with submission and acceptance dates (485 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 9 daysPublisher website ·
- Acceptance to publication
- 5 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,890 / EUR 3,640 / GBP 3,110 / JPY 482,480 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Cancer Media Group
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2010
- ISSN
- 2152-2650
- Electronic ISSN
- 2152-2669
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
FAQ
Frequently asked questions about Clinical Lymphoma Myeloma & Leukemia
What CAS zone is Clinical Lymphoma Myeloma & Leukemia in?
In the 2025 upgraded edition of the CAS Journal Ranking, Clinical Lymphoma Myeloma & Leukemia is in Zone 4 of Medicine, and in Zone 4 of the minor category Hematology / Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Clinical Lymphoma Myeloma & Leukemia?
The latest impact factor listed by LetPub is 3.9; CiteScore 2.6, h-index 67.
How long does peer review take at Clinical Lymphoma Myeloma & Leukemia?
Based on the dates recorded on 101 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 44 days (interquartile range 29–58 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Clinical Lymphoma Myeloma & Leukemia based?
Of the 84 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (59), France (3) and Italy (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Clinical Lymphoma Myeloma & Leukemia?
According to LetPub and DOAJ records, Clinical Lymphoma Myeloma & Leukemia is indexed in SCIE and Scopus.
Is Clinical Lymphoma Myeloma & Leukemia open access, and what is the APC?
Clinical Lymphoma Myeloma & Leukemia is a hybrid journal. For open-access publication: APC about USD 3,890.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .